PMID- 18179310
OWN - NLM
STAT- MEDLINE
DCOM- 20080317
LR  - 20151119
IS  - 1064-1297 (Print)
IS  - 1064-1297 (Linking)
VI  - 15
IP  - 6
DP  - 2007 Dec
TI  - Aripiprazole: effectiveness and safety under naturalistic conditions.
PG  - 569-75
LID - 10.1037/1064-1297.15.6.569 [doi]
AB  - A retrospective study was conducted to examine aripiprazole's effectiveness and 
      safety in a naturalistic treatment setting in both inpatients and outpatients 
      affected by schizophrenia and other psychotic disorders. All patients with 
      schizophrenia, schizoaffective and delusional disorders, and schizoid and 
      schizotypal personality disorders treated with aripiprazole from March 1, 2005, 
      to March 1, 2006, in the authors' community mental health service were divided 
      into outpatient (n=26) and inpatient (n=17) groups; the average treatment periods 
      were 204 days and 25 days, respectively. Effectiveness was evaluated by 
      improvement of symptoms (a 25% reduction of Brief Psychiatric Rating Scale [BPRS] 
      score from baseline) and functioning level (a 50% increase of Global Assessment 
      of Functioning [GAF] scale score from baseline), as well as dropout rate. Adverse 
      effects and their impact on treatment course were also evaluated. The final 
      scores of the 2 scales showed a statistically significant difference from 
      baseline (BPRS: p<.001 in the 2 groups; GAF: p<.005 in inpatients, p<.001 in 
      outpatients). The average improvements in BPRS and GAF were 54% and 35%, 
      respectively, in outpatients and 71% and 71% in inpatients. Side effects included 
      anxiety, psychomotor agitation, insomnia, and psychotic symptom worsening. The 
      dropout rate was 24% in inpatients and 23% in outpatients, largely because of the 
      aforementioned side effects. The data, though limited by the small sample and 
      naturalistic methodology, suggest that aripiprazole may be effective for both 
      long- and short-term treatment, with a greater improvement among inpatients and a 
      similar dropout rate between groups.
CI  - (c) 2008 APA, all rights reserved.
FAU - Di Lorenzo, Rosaria
AU  - Di Lorenzo R
AD  - Department of Mental Health, AUSL-MODENA, Presidio Psichiatrico di Diagnosi e 
      Cura 1, Policl via del Pozzo 71, 141100, Modena, Italy. saradilorenzo1@alice.it
FAU - Amoretti, Alessandra
AU  - Amoretti A
FAU - Forghieri, Matilde
AU  - Forghieri M
FAU - Fiorini, Fiorenza
AU  - Fiorini F
FAU - Genedani, Susanna
AU  - Genedani S
FAU - Rigatelli, Marco
AU  - Rigatelli M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Exp Clin Psychopharmacol
JT  - Experimental and clinical psychopharmacology
JID - 9419066
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Piperazines)
RN  - 0 (Quinolones)
RN  - 82VFR53I78 (Aripiprazole)
SB  - IM
MH  - Adult
MH  - Antipsychotic Agents/adverse effects/*therapeutic use
MH  - Anxiety/chemically induced
MH  - Aripiprazole
MH  - Female
MH  - Humans
MH  - Inpatients/statistics & numerical data
MH  - Italy
MH  - Male
MH  - Middle Aged
MH  - Outpatients/statistics & numerical data
MH  - Piperazines/adverse effects/*therapeutic use
MH  - Psychiatric Status Rating Scales/statistics & numerical data
MH  - Psychomotor Agitation/etiology
MH  - Psychotic Disorders/*drug therapy
MH  - Quinolones/adverse effects/*therapeutic use
MH  - Recurrence
MH  - Retrospective Studies
MH  - Schizoid Personality Disorder/drug therapy
MH  - Schizophrenia, Paranoid/drug therapy
MH  - Schizotypal Personality Disorder/drug therapy
MH  - Sleep Initiation and Maintenance Disorders/chemically induced
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2008/01/09 09:00
MHDA- 2008/03/18 09:00
CRDT- 2008/01/09 09:00
PHST- 2008/01/09 09:00 [pubmed]
PHST- 2008/03/18 09:00 [medline]
PHST- 2008/01/09 09:00 [entrez]
AID - 2007-18976-008 [pii]
AID - 10.1037/1064-1297.15.6.569 [doi]
PST - ppublish
SO  - Exp Clin Psychopharmacol. 2007 Dec;15(6):569-75. doi: 10.1037/1064-1297.15.6.569.